SCHEMBL6091441

SCHEMBL6091441

CC(C)Oc1ccc(C(=O)Nc2c(C(=O)[O-])n(Cc3cccc(Cl)c3)c3cc(-c4cc(F)cc(F)c4)ccc23)cc1.[Na+]

nearest known ligand 0.41

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG known ✓ P37231 5/20 0.37
ALOX5 known ✓ P09917 1/20 0.37
PTGIR known ✓ P43119 1/20 0.37
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41
S1PR3 Q99500 2/20 0.39
TP53 P04637 2/20 0.38
MAPT P10636 1/20 0.38
PTGES O14684 1/20 0.37
MDM2 Q00987 4/20 0.37
MCL1 Q07820 3/20 0.37
PPARA Q07869 4/20 0.37
CYP2C9 P11712 1/20 0.37
EGFR P00533 1/20 0.37
CHRM4 P08173 1/20 0.37
ADRB1 P08588 1/20 0.37
ADRA2A P08913 1/20 0.37
ADRB3 P13945 1/20 0.37
DRD2 P14416 1/20 0.37
ADRA2B P18089 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091176 0.93 PTGES (0.43) GRIN1GRIN2BS1PR3TP53MAPT
SCHEMBL6091449 0.92 PTGES (0.42) GRIN1GRIN2BS1PR3TP53MAPT
SCHEMBL6091437 0.92 PTGES (0.42) GRIN1GRIN2BS1PR3TP53MAPT
SCHEMBL6089483 0.85 TP53 (0.44) S1PR3TP53PTGESPPARGMDM2
SCHEMBL6090994 0.84 TP53 (0.46) GRIN1GRIN2BTP53MAPTPTGES
SCHEMBL6091379 0.83 YWHAH (0.45) TP53MAPTPTGESMDM2MCL1
SCHEMBL6092477 0.83 PTGER4 (0.43) GRIN1GRIN2BS1PR3PTGESPPARG
SCHEMBL6091719 0.82 LMNA (0.39) S1PR3MAPTPPARGRXFP1USP36
SCHEMBL6093252 0.82 GRIN1 (0.45) GRIN1GRIN2BTP53MAPTPTGES
SCHEMBL6092460 0.81 RXFP1 (0.44) S1PR3TP53MAPTPPARGCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160879-A1 Indoles useful in the treatment of inflammation BIOLIPOX AB (SE) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160879-A1 Indoles useful in the treatment of inflammation IDO1, PTGS1, IDO2 PPARG 481/4885ALOX5 30/4885PTGIR 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.